September 17^th, 2024– As CURA enters the latter half of the year, we are pleased to announce the successful completion of our Pre-A series funding round. CURA has raised over $4 million, led by a prominent asset management firm. Underscoring strong confidence in CURA's strategic direction and technological advancements.

CURA remains on track to outpace its operational and development goals. This new funding will fuel further innovations and expedite our product timeline, with an eye toward our major releases slated for 2025.

In recent months, CURA has forged valuable new relationships in both local and international markets. We have successfully implemented two of our A20 units with zero service calls, including a turn-key lab built from the ground up. Our team's hard work and dedication have driven these achievements, positioning CURA for a promising 2025.

"Our team's relentless dedication and innovative spirit have been instrumental in reaching these milestones," said CEO Dr. Jia He. "This funding not only validates our vision but also enhances our capability to lead and transform the diagnostics landscape."

CURA is set to continue its trajectory of growth and innovation into the new year and beyond. More updates will follow as we approach our 2025 product launches, promising exciting advancements in diagnostic technology.

About CURA Diagnostics: CURA Diagnostics is dedicated to pioneering advanced diagnostic tools that enhance patient care and clinical efficiency. Our commitment to innovation is reflected in our robust product pipeline and our rapidly expanding global footprint.